Cancer immunotherapy
PRINCIPAL INVESTIGATORS
- Sandra Fontanals Martínez
- Rafael Moreno Olié
CLINICAL RESEARCHERS
- Oscar Buisán Rueda
- Eduard Fort Casamartina
- Miriam Garzon Ransanz
- Javier Gavira Diaz
- Pablo Nadal Feced
POSTDOCTORAL RESEARCHERS
- Marcel Costa García
- Gabriel Espinosa Carrasco
- Lidia Franco Luzon
- Carlos Lopez Gil
PREDOCTORAL RESEARCHERS
- Sebastian Ciro Carne Martin
- Luis Paul Del Carpio Huerta
- Pau Fiol Mata
- Juan Antonio Marin Jimenez
- Carla Perez Vazquez
- Mar Tarinas Torrent
SCIENTIFIC SUPPORT
- Carles Codony Servat
- Ainhoa Muñoz Merino
- Silvia Torres Manjon
Cancer
Oncobell
Scientific production
21
PAPERS
Average IF: 18,24
4
LED PAPERS
Average IF: 22,45
9 PUBLICATIONS IN FIRST DECILE
16 PUBLICATIONS IN FIRST QUARTILE
13 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Gratzke,C;Özgüroglu,M;Peer,A;Sendur,M;Retz,M;Goh,JC;Loidl,W et al, Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study., Ann. Oncol., 2025;36(8):964-975, doi:10.1016/j.annonc.2025.05.008
- Garcia Muro,X;Valderrama,PB;Medina Colmenero,A;Etxaniz,O;Gironés Sarrió,R;Juan Fita,MJ;Costa García,M et al, Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial., Clin Cancer Res, 2025;31(4):659-666, doi:10.1158/1078-0432.CCR-24-2636
- del Carpio,LP;Varela,M;Portu,M;Villatoro,S;Purqueras,E;Goma,M;Lorenzo,D et al, Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations, Eur. J. Cancer, 2025;226115591-115591, doi:10.1016/j.ejca.2025.115591
- Martín Lluesma,S;Dafni,U;Vervita,K;Karlis,D;Dimopoulou,G;Tsourti,Z;Villacampa,G et al, Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis., Ann. Oncol., 2025;36(8):909-919, doi:10.1016/j.annonc.2025.04.001
- Fizazi,K;Chi,KN;Shore,ND;Herrmann,K;de Bono,JS;Castellano,D;Piulats,JM et al, Final overall survival and safety analyses of the phase III PSMAfore trial of [ 177 Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer, Ann. Oncol., 2025;36(11):1319-1330, doi:10.1016/j.annonc.2025.07.003
Research highlights
PROJECTS
4 Granted Competitive project
17 Ongoing Competitive projects
8 Started clinical trials
31 Ongoing clinical trials
2 Ongoing non competitive projects
INNOVATION
2 licenses
5 Patents
PUBLISHED WORKS
1 Thesis
NETWORKS
AdenoNet
CIBERONC
AGAUR-SGR 2021 00895
TERAV+
Selected projects
- PI24/01710. Identificación de debilidades inmunes del cáncer de próstata metastásico. INMUNE-PC. Instituto de Salud Carlos III (ISCIII). Budget: 315.000€. 2025-2027. PI: JOSEP MARÍA PIULATS RODRÍGUEZ.
- PID2023-146637OB-C21. Fomentar la inmunidad antitumoral con adenovirus oncolíticos armados con proteínas formadoras de poros o epítopos formadores de tríadas. Ministerio de Ciencia e Innovación. Budget: 262.500€. 2024-2027. PI: RAMON ALEMANY BONASTRE.
- PI23/00385. Células troncales mesenquimales como vehículo celular de un adenovirus oncolitico codificante de un activador biespecifico de célula T (BiTE) frente a EGFR para el tratamiento del glioblastoma. Instituto de Salud Carlos III (ISCIII). Budget: 95.625€. 2024-2026. PI: RAFAEL MORENO OLIÉ.
- CLIP-CRI-2022. Generation of personalized TCR therapy against GNAQ/11 Q209L mutations in Uveal Melanoma. PREMI-UM. CANCER RESEARCH INSTITUTE CRI. Budget: 182.848,77€. 2023-2026. PI: JOSEP MARÍA PIULATS RODRÍGUEZ / RAMON ALEMANY BONASTRE.
- PID2020-119692RB-C21. Inducción de muerte celular inmunogénica en tumores mediante el uso de adenovirus oncolíticos armados. Ministerio de Ciencia e Innovación. Budget: 266.200€. 2021-2025. PI: RAMON ALEMANY BONASTRE.